VDR rs2228572: Understanding the TaqI Variant
The rs2228572 variant is a common genetic change located within the VDR gene, which encodes the vitamin D receptor. Researchers have investigated this variant, often called TaqI, for potential associations with bone mineral density and how the body responds to vitamin D supplementation.
What each genotype means
Typical bone density profile
You carry two copies of the C allele (historically designated as the restriction site 'T' allele in TaqI RFLP assays). Published studies generally link this genotype to standard vitamin D receptor signaling, baseline seasonal vitamin D responsiveness, and average bone mineral density. However, overall clinical evidence remains limited and findings vary across different ancestral groups.
Found in approximately 30% to 45% of individuals globally, though frequencies vary by ancestry.
Intermediate receptor response
You have one copy of the C allele and one copy of the T allele for this synonymous variant (often noted as Tt in restriction enzyme literature). Research suggests an intermediate profile for bone mineral density and vitamin D pathway efficiency relative to the homozygous genotypes. Because scientific findings show mixed effects across populations, carrying this genotype represents only a modest trait association.
Carried by approximately 40% to 50% of people across most global populations.
Modestly reduced bone density tendency
You carry two copies of the T allele (frequently termed the 'tt' genotype in classic TaqI literature). Some association studies report slight reductions in bone mineral density and altered seasonal vitamin D utilization in carriers of this genotype, but results across diverse cohorts remain inconsistent and limited. This finding does not diagnose bone loss or vitamin deficiency, so maintain standard wellness checkups with your healthcare provider.
Present in roughly 10% to 20% of people of European descent and somewhat less common in East Asian populations.
What is rs2228572?
The rs2228572 variant is a single nucleotide polymorphism (SNP) found in the VDR gene. In scientific literature, this specific variant is frequently referred to as the TaqI polymorphism. It is classified as a synonymous variant, meaning that the change in the DNA sequence does not alter the amino acid sequence of the resulting protein. Because it does not change the protein structure, researchers often investigate whether it might influence gene expression, mRNA stability, or if it serves as a genetic marker that is inherited alongside other functional changes in the nearby region of the genome. It is one of several well-studied polymorphisms in the VDR gene, alongside others like BsmI, ApaI, and FokI.
The Role of the VDR Gene
The VDR gene provides the instructions for creating the vitamin D receptor protein. This protein acts as a transcription factor, meaning it binds to specific sequences of DNA to turn genes on or off. The primary role of the vitamin D receptor is to mediate the effects of calcitriol, the active form of vitamin D, throughout the body. By binding to vitamin D, the receptor helps regulate calcium homeostasis, which is essential for maintaining healthy bones and teeth. Beyond bone health, the VDR protein is involved in various biological processes, including immune system regulation, cell growth, and differentiation. Because vitamin D is critical for many physiological functions, variations in the VDR gene have been the subject of extensive research to see if they influence how individuals process vitamin D or maintain bone density.
Research and Evidence
The evidence linking rs2228572 to health outcomes is considered limited and often conflicting. Early studies in the 1990s suggested potential associations between VDR polymorphisms and bone mineral density or osteoarthritis risk. However, subsequent large-scale meta-analyses have frequently failed to replicate these findings, showing no consistent relationship between the TaqI polymorphism and fracture risk or bone loss. More recent research has shifted toward investigating whether this variant influences the body's response to vitamin D supplementation. Some studies suggest that certain genotypes might be associated with a better response to vitamin D intake, but these results are not definitive. Because the evidence is mixed and often varies by population, it is important to view these associations as statistical observations rather than established medical facts. The scientific community continues to debate the clinical significance of this variant.
What You Can Do With This Information
Genetic information regarding the rs2228572 variant should be interpreted with caution. Because the associations with bone health and vitamin D efficiency are not robust or clinically validated, this variant cannot be used to diagnose conditions like osteoporosis or to predict individual vitamin D requirements. If you are concerned about your bone health or vitamin D levels, the most effective approach is to consult with a healthcare professional. They can order standard blood tests to measure your actual vitamin D levels and assess your bone density through clinical imaging. Never use genetic test results to make decisions about supplementation or medication. Always discuss any changes to your health regimen with your doctor or a registered pharmacist, as they can provide guidance based on your complete medical history and current clinical status.
How common is this variant?
The minor allele frequency for rs2228572 is approximately 0.30 to 0.45 globally, though frequencies can vary significantly across different ancestral populations.
Frequently asked questions
Can I use my rs2228572 genotype to determine my vitamin D dosage?
No. Current scientific evidence is not strong enough to support using this genetic variant to guide vitamin D dosing. You should always consult with a healthcare provider to determine the appropriate vitamin D intake based on blood tests and your specific health needs.
Is rs2228572 the same as the TaqI polymorphism?
Yes, rs2228572 is commonly referred to as the TaqI polymorphism in scientific literature. It is one of several VDR gene variants that researchers have studied for decades.
Does having a specific VDR genotype mean I have weak bones?
No. Genetic variants like rs2228572 are only one small factor in a complex system that determines bone health. Factors such as diet, physical activity, age, and overall lifestyle have a much larger impact on bone mineral density than this single variant.
Why do some studies show an association and others do not?
This is common in genetic research, especially for complex traits like bone density. Differences in study design, sample sizes, and the ancestral backgrounds of the participants can lead to conflicting results, which is why the evidence for this variant is considered limited.
Sources & further reading
Educational information only, last refreshed 10/18/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2228572?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in VDR
Variant in the promoter region (Cdx2 site) of the vitamin D receptor gene associated with altered intestinal calcium absorption and bone mineral density.
This variant in the Vitamin D receptor gene is associated with susceptibility to Type 1 Diabetes and autoimmune thyroid disease.
Promoter polymorphism (Cdx2) in the VDR gene associated with bone mineral density and vitamin D metabolism.
Common polymorphism (TaqI variant) in the vitamin D receptor affecting mRNA stability and bone mineral density.
Known as the TaqI polymorphism, this variant is located in the 3' UTR of the VDR gene and is associated with altered mRNA stability, influencing vitamin D signaling, cancer cachexia susceptibility, and gastric cancer risk.
Variant in the VDR promoter (Cdx-2 binding site) associated with bone mineral density and calcium absorption efficiency.